Results from the Solithromycin International Surveillance Program (2014)

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Macrolide resistance is a growing concern in treating bacterial infections.
• Solithromycin, a fourth-generation macrolide (fluoroketolide), exhibits enhanced activity against macrolide-resistant bacteria.
• Community-acquired bacterial pneumonia remains a significant global health challenge.

Purpose of the Study:

• To evaluate the in vitro activity of solithromycin against a contemporary collection of bacterial pathogens.
• To compare solithromycin's efficacy against other macrolides like azithromycin and telithromycin.
• To assess solithromycin's activity across different geographic regions.

Main Methods:

• Reference broth microdilution method was employed.
• A total of 6,115 bacterial isolates were tested, including Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, and beta-hemolytic streptococci.
• Isolates were collected globally in 2014.

Main Results:

• Solithromycin demonstrated potent activity against Streptococcus pneumoniae (MIC50/90, 0.008/0.12 μg/ml), significantly exceeding azithromycin and telithromycin.
• The drug was highly active against beta-hemolytic streptococci (MIC50/90, 0.015/0.03 μg/ml).
• Solithromycin showed promising activity against Staphylococcus aureus, including methicillin-resistant strains, and Moraxella catarrhalis.

Conclusions:

• Solithromycin exhibits potent in vitro activity against major pathogens causing community-acquired bacterial pneumonia.
• Its efficacy against macrolide-resistant strains supports its potential as a treatment option.
• Further clinical development of solithromycin for community-acquired bacterial pneumonia is warranted.